You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Public Rights-of-Way Assessment Instrumentation to Determine Accessibility

    SBC: BENEFICIAL DESIGNS INC            Topic: 081FH2

    City planners and engineers need detailed assessments of public rights-of-way to evaluate existing conditions, determine compliance with draft accessibility guidelines, and plan reconstruction projects. Current assessment methods are inadequate and inefficient due to the time and resources required. This project will develop an automated public rights-of-way assessment process and the measuremen ...

    SBIR Phase II 2010 Department of Transportation
  2. Accelerated Discovery and Development of New Pain Therapeutics

    SBC: AESTUS THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Neuropathic pain is a common complication of cancer, diabetes mellitus, viral infections, and other causes. Although physicians currently employ a variety of treatments to manage moderate to severe neuropathic pain, including non-steroidal anti-inflammatory drugs, opioids, tricyclic antidepressants, anti- seizure medications, serotonin-norepinephrine reupta ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Peptide inhbitors of influenza entry-FAST TRACK

    SBC: Autoimmune Technologies, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Between 10% and 20% of the United State population suffer from seasonal influenza each year. While most individuals recover from influenza in one to two weeks, the very young, the elderly and persons with chronic medical conditions can develop post-flu pneumonia and other lethal complications. The causative agent of influenza is influenza virus, a myxovirus tha ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Development and Validation of a FISH-Based Renal Cancer Detection Assay

    SBC: Gentris Corporation            Topic: NCI

    DESCRIPTION (provided by applicant): Increased routine use of state-of-the-art imaging techniques has resulted in a higher incidence of small incidentally discovered renal masses, benign and malignant. A large proportion of patients with such masses, are within an older, more frail population and for renal cell carcinoma (RCC), 60-70% of patients now present asymptomatically. Treatment recommendat ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. RFID Based Tracking System for Ultra-Low Temperature Sample Repositories

    SBC: BIOTILLION LLC            Topic: NCRR

    DESCRIPTION (provided by applicant): The number of archived biological samples is very large and ever growing. Maintaining large collections of these samples is fraught with difficulties arising from inadequate labeling technologies, the inability to automatically locate the samples and a lack of robust connection between the physical sample and archiving software. We propose to develop a system t ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced Electrostatic Computation in Molecular Dynamics

    SBC: CONTINUUM DYNAMICS INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Advances in computational hardware and molecular modeling techniques have revolutionized our ability to simulate electrostatic interactions, which play a fundamental role in the conformational stability, structure, folding and function of biomolecules. One important near-term application of these developments drawing both theoretical and commercial interests is ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Camptothecin Analogs for Cancer Therapy

    SBC: DEKK-TEC INC            Topic: NCI

    DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic tumor tissues, characteristic of fast growing cancers that characteristically have deficient vasculature and outgrow their blood supply. Both in vitro and in vivo studies support the potential useful ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. A Self-Monitoring Artificial Vascular Graft

    SBC: DVX, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Several hundred thousand people in the USA each year require artificial blood vessels, grafts , to be placed in their legs because of failing circulation. Sixty thousand of these patients require artificial prosthetic grafts. Unfortunately, many of the artificial grafts become occluded in just a few years (almost 40 % fail within a year), leading to leg amputa ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. CircuLite's Circulatory Support System in Children and Infants

    SBC: CIRCULITE, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Sophisticated ventricular assist devices (VADs) are now routinely used for bridge to recovery, or bridge to transplant in heart failure patients. However, the success of the VADs' applications in adults has not been translated into that in pediatric application, due to the delays in the miniaturization process of these devices. To date, the need of VADs for inf ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy

    SBC: IMMUNOMEDICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): As a continuation of a successful Phase I SBIR, this Phase II application is directed towards the further development of a novel immunocytokine, named 20-2b, for improved therapy of B-cell lymphomas. In the United States, there were 65,980 new cases of non-Hodgkin lymphoma (NHL) and 19,500 deaths from this disease in 2009. Of all B-cell NHL, 55% are of the DLBC ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government